Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study

Conference contribution


Publication Details

Author(s): Hirschfield G, Boudes P, Bowlus C, Gitlin N, Michael G, Harrison S, Gordon SC, Aspinall R, Doerffel Y, Kremer A, Sheridan D, Bacon B, Berg C, Borg B, Hassanein T, Odin J, Shiffman M, Thuluvath PJ, Thorburn D, Bernstein D, Buggisch P, Corless L, Levy C, Mayo MJ, Swain MG, Vierling J, Woerns MA, Steinberg AS, Bergheanu S, Choi YJ, Varga M, Martin R, Mcwherter C, Jones D
Publisher: ELSEVIER SCIENCE BV
Publishing place: AMSTERDAM
Publication year: 2018
Conference Proceedings Title: JOURNAL OF HEPATOLOGY
Pages range: S105-S106
ISSN: 0168-8278


FAU Authors / FAU Editors

Kremer, Andreas PD Dr.
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie


External institutions with authors

Asklepios Kliniken Verwaltungsgesellschaft mbH
Atlanta Gastroenterology Associates
Bon Secours Liver Institute of Richmond
Charité - Universitätsmedizin Berlin
CymaBay Therapeutic
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Henry Ford Health System (HFHS)
Houston Texas Medical Center
Hull and East Yorkshire Hospitals NHS Trust
Icahn School of Medicine at Mount Sinai
Institute for Digestive Health and Liver Disease
Johannes Gutenberg-Universität Mainz
Pinnacle Clinical Research
Queen Alexandra Hospital
Royal Free Hospital
Saberg Clinical Research
Saint Louis University (SLU)
Southern Therapy and Advanced Research LLC
Universitätsklinikum Tübingen
University Hospitals Plymouth NHS Trust
University of Birmingham
University of Calgary
University of California Davis (UCDAVIS)
University of Miami
University of Newcastle (UoN)
University of Texas Southwestern Medical Center (UT Southwestern)


How to cite

APA:
Hirschfield, G., Boudes, P., Bowlus, C., Gitlin, N., Michael, G., Harrison, S.,... Jones, D. (2018). Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study. In JOURNAL OF HEPATOLOGY (pp. S105-S106). Paris, FR: AMSTERDAM: ELSEVIER SCIENCE BV.

MLA:
Hirschfield, G., et al. "Treatment efficacyand safety of seladelpar, a selective peroxisome proliferator-activated receptor delta agonist, in primary biliary cholangitis patients: 12-and 26-week analysis from an ongoing international, randomized, dose raging phase 2 study." Proceedings of the International Liver Congress (ILC), Paris AMSTERDAM: ELSEVIER SCIENCE BV, 2018. S105-S106.

BibTeX: 

Last updated on 2019-28-03 at 09:23